These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 17355549

  • 1. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M.
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [Abstract] [Full Text] [Related]

  • 3. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB.
    Neurology; 2003 Feb 25; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract] [Full Text] [Related]

  • 4. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ, Nurmikko TJ, Friede T, Young CA.
    Neurology; 2005 Sep 27; 65(6):812-9. PubMed ID: 16186518
    [Abstract] [Full Text] [Related]

  • 5. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH.
    Neurology; 2002 May 14; 58(9):1404-7. PubMed ID: 12011290
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
    Wade DT, Robson P, House H, Makela P, Aram J.
    Clin Rehabil; 2003 Feb 14; 17(1):21-9. PubMed ID: 12617376
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M, Vila C.
    Eur Neurol; 2015 Feb 14; 74(3-4):178-85. PubMed ID: 26571097
    [Abstract] [Full Text] [Related]

  • 11. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L, Mori L, Canneva S, Colombano F, Currà A, Fattapposta F, Bandini F, Capello E, Abbruzzese G, Trompetto C.
    Int Clin Psychopharmacol; 2016 Jul 14; 31(4):232-9. PubMed ID: 27003093
    [Abstract] [Full Text] [Related]

  • 12. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT, Makela P, Robson P, House H, Bateman C.
    Mult Scler; 2004 Aug 14; 10(4):434-41. PubMed ID: 15327042
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Metz L, Page S.
    Lancet; 2003 Nov 08; 362(9395):1513. PubMed ID: 14615102
    [No Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A, Broughton J.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec 08; 16(6):771-779. PubMed ID: 26750641
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
    Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P, Sativex Spasticity Study Group.
    Eur J Neurol; 2011 Sep 08; 18(9):1122-31. PubMed ID: 21362108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.